Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

5 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
6(85.7%)
Phase 1
1(14.3%)
7Total
Phase 2(6)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06623110Phase 2Recruiting

Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

Role: lead

NCT06239220Phase 2Recruiting

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Role: lead

NCT05057247Phase 2Completed

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Role: lead

NCT06805617Phase 2Recruiting

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Role: lead

NCT06940180Phase 2Recruiting

Toripalimab With Chemotherapy for Sinus Cancer

Role: lead

NCT05774899Phase 1Recruiting

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Role: lead

NCT05010629Phase 2Active Not Recruiting

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Role: lead

All 7 trials loaded